Company Reports

Wuxi Bio's first half of 2026 revenue grew 18% year-on-year to CNY 11.7 billion, driven by 169 new projects, while operating margin expanded 450 basis points from lower overhead and more biosimilar projects, which yield greater pricing due to their molecular complexity.

WuXi Biologics should continue to maintain a leading market position in China as well as globally, given that over 60% of revenue comes from North America, where many of its clients are leading-edge pharmaceutical firms. WuXi has been investing heavily in manufacturing capacity to meet rising demand. The growing number of Chinese biotech companies has been a tailwind; they prefer a domestic champion, which should add to WuXi’s pipeline. Unlike big US companies, Chinese biotech startups often lack in-house manufacturing capabilities, leading to heavy reliance on external partners and the need for end-to-end development and manufacturing services. WuXi’s integrated platform, technology, and regulatory record provide Chinese biotech startups with services ranging from discovery to commercial manufacturing efficiently.

WuXi Biologics' share price has increased more than 15% since the end of July.

Wuxi Bio's second-half 2025 revenue grew 17% year on year to CNY 11.8 billion, driven by greater late-stage projects that command higher pricing, and a 670-basis-point expansion in operating margin.

We initiate coverage of WuXi Biologics with a Narrow Economic Moat Rating, Very High Uncertainty Rating, and HKD 42 fair value estimate, which reflects 20% upside based on the March 12 close.

WuXi Biologics should continue to maintain a leading market position in China as well as globally, given that over 60% of revenue comes from North America, where many of its clients are leading-edge pharmaceutical firms. WuXi has been investing heavily in manufacturing capacity to meet rising demand. The growing number of Chinese biotech companies has been a tailwind; they prefer a domestic champion, which should add to WuXi’s pipeline. Unlike big US companies, Chinese biotech startups often lack in-house manufacturing capabilities, leading to heavy reliance on external partners and the need for end-to-end development and manufacturing services. WuXi’s integrated platform, technology, and regulatory record provide Chinese biotech startups with services ranging from discovery to commercial manufacturing efficiently.

We will discontinue analyst coverage of WuXi Biologics on or about Nov. 12, 2025.

WuXi Biologics management revised its 2025 full-year revenue annual growth range to 14%-16% from 12%-15%, following the first-half revenue growth rate of 16.1%. Its gross margin also expanded to 42.7%, 360 basis points higher than that of last year.

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations with its "follow and win the molecule" and global dual sourcing strategies. It provides end-to-end services for biologic drugs, from drug discovery to clinical and commercial manufacturing. Unlike its global peers, WuXi specializes in biologic therapeutic modalities. It has one of the largest bioreactor capacities with manufacturing sites worldwide. Riding on the structural shift from small molecule drugs to biologic drugs, WuXi has been growing at a compound annual rate of 47.7% for the past nine years, much faster than global pharmaceutical sales or global CDMOs.

US President Donald Trump said that the US tariffs on pharmaceutical imports may increase to 150% or even further to 250% in one to one and a half years.

We have raised our fair value estimate for narrow-moat-rated WuXi Biologics to HKD 26.60 per share from HKD 24.60 following better-than-expected 2024 results and strong guidance for 2025. Total projects increased to 817, higher than our initial forecast of 746. We believe customer stickiness, despite geopolitical uncertainty, supports our moat rating. After a rally of nearly 50% year to date, the shares appear fairly valued to us.

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations with its "follow and win the molecule" and global dual sourcing strategies. It provides end-to-end services for biologic drugs, from drug discovery to clinical and commercial manufacturing. Unlike its global peers, WuXi specializes in biologic therapeutic modalities. It has one of the largest bioreactor capacities with manufacturing sites worldwide. Riding on the structural shift from small molecule drugs to biologic drugs, WuXi has been growing at a compound annual rate of 47.7% for the past nine years, much faster than global pharmaceutical sales or global CDMOs.

China healthcare stocks under our coverage, with the exception of medical distributors, have surged 10% to 50% since the end of January, following excitement over DeepSeek. While artificial intelligence may help improve efficiency in the sector, we don’t know if and when the benefits will materialize, so we believe the recent share price rally reflects a shift in investor sentiment on previously oversold stocks. Namely, Sino Biopharm (up 19%), WuXi Biologics (up 34%), and KingMed (up 56%), are reaching or surpassing our fair value estimates. However, we think CSPC (up 10%), Innovent (up 16%), and Adicon (up 21%) are still attractive.

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing" strategies. Simply put, it provides end-to-end services for biological drugs from drug discovery all the way to clinical and commercial manufacturing. Unlike its global peers, WuXi specializes in biological therapeutic modalities. It has one of the largest bioreactor capacities with manufacturing sites worldwide. Riding on the structural shift from small molecule drugs to biologic drugs, WuXi has been growing at a compound annual growth rate of 53.3% for the past eight years, much faster than that of global pharmaceutical sales or global CDMOs.

We cut our fair value estimate on narrow-moat-rated WuXi Biologics to HKD 24.60 per share from HKD 28.10 as we lower our project growth assumption for the next decade. We take a fresh look after WuXi divested a vaccine manufacturing site in Ireland, indicating reduced capacity planning. Although the US Biosecure Act has yet to become law, the uncertainty is weighing on demand for Wuxi’s services. We expect global pharmaceutical or biotechnology companies to be more cautious when signing new long-term contracts with Chinese players as geopolitical risks remain high. While we view WuXi's shares as cheap, currently trading at a price/book ratio of around 1.4 times, we caution that the share price may be very volatile due to headline risks.

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing" strategies. Simply put, it provides end-to-end services for biological drugs from drug discovery all the way to clinical and commercial manufacturing. As such, WuXi has one of the largest bioreactor capacities for biological drug products. As a result, WuXi has been growing at a compound annual growth rate of 53.3% for the past eight years, much faster than that of global pharmaceutical sales or global CDMOs.

Following interim results from narrow-moat WuXi Biologics that are largely in line with our expectations, we keep the bulk of our assumptions unchanged but raise our capital expenditure following management guidance of increased spending in 2025. This nudges our fair value estimate down to HKD 28.10 per share from HKD 28.60. However, the lack of revenue growth disappointed the market, leading to a drop in WuXi Bio’s share price by 7.8% as of the midtrading session. We continue to believe that WuXi Bio is oversold. Understandably, investors remain nervous, given that WuXi Bio stands to lose projects due to the Biosecure Act in the US. But indications so far are that its project orderbook is intact and growth guidance is maintained. Our fair value estimate assumes that WuXi Bio’s client base will eventually be largely China- and ex-US-driven, so we do think the shares are oversold. We think that when the act becomes law, it will allow greater clarity, reducing uncertainty as to what WuXi Bio will be able to undertake for its global clients.

In WuXi Biologics’ upcoming earnings, we think the most important update to watch out for is project addition because we believe it reflects potential concerns over the acceptance of WuXi Bio by the global biotech and biopharma industry given the likely impending implementation of the Biosecure Act. Of note are the contract-developing projects in the early stages, potentially having at least 10 years to run until the end of commercial manufacturing.

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing" strategies. Simply put, it provides end-to-end services for biological drugs from drug discovery all the way to clinical and commercial manufacturing. As such, WuXi has one of the largest bioreactor capacities for biological drug products. DPs are the noncommercialized therapeutic products used in the clinical trial phase. As a result, WuXi has been growing at a compound annual growth rate of 53.3% for the past eight years, much faster than that of global pharmaceutical sales or global CDMOs.

We lower WuXi Biologics' fair value estimate to HKD 28.60 per share from HKD 57.90 per share as we capture a possible slowdown in projects from geopolitical risks. While 2023 revenue growth of 11.6% beat our expected 10.4%, we think both project increase and revenue growth may be challenging in the next three years due to uncertainties around the Biosecure Act. Although the stock is trading at a nearly 50% discount to our valuation, we caution that WuXi's share price will remain very volatile and very sensitive to political rhetoric.